

GETUG



Communications Congrès 2021

Type de communication	Titre	Prem Auteur	Congrès
Poster	Prognosis impact of serous metastases (SMs) in clear cell renal cell carcinoma patients in the GETUG-AFU-26 NIVOREN phase II trial	CULINE Stéphane	ASCO
Présentation orale	A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer: first results of PEACE-1	FIZAZI Karim	ASCO
Poster	Abstract 331: Safety and efficacy of nivolumab in older patients (pts) with renal cell carcinoma: Results of a sub-group analysis of the GETUG-AFU 26 NIVOREN multicenter phase II study.	MOUREY Loic	ASCO GU
Poster	Abstract 359: Association of statins and nivolumab activity in patients with metastatic renal cell carcinoma (mRCC): Results from the phase II nivoren—GETUG AFU 26 trial.	COLOMBA Emeline	ASCO GU
Présentation orale	PEACE1: Abiraterone acetate plus prednisone added to androgen deprivation therapy and docetaxel in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): detailed analysis of radiographic progression-free survival in the PEACE-1 phase 3 study	FIZAZI Karim	EAU
Poster	Abstract : Assessment of bleomycin pulmonary toxicity in men with poor-prognosis non-seminomatous germ-cell tumors treated in the GETUG 13 phase III trial	NAOUN Natacha	ESMO
Poster	#2387 - A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse: the PEACE 2 trial from Unicancer	BLANCHARD Pierre	ESMO
Poster	Antibiotic (ATB) therapy and outcome from Nivolumab (N) in metastatic Renal Cell Carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN Multicentric Phase II Study.	DEROSA Lisa	ESMO
Présentation orale	Darolutamide maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents (NHA) and non-progressive disease after subsequent treatment with a taxane: A multicenter randomized double-blind placebo-controlled phase II trial (SAKK 08/16)	Richard Cathomas	ESMO
Présentation orale - session présidentielle	A phase 3 trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1	FIZAZI Karim	ESMO
Présentation orale	655MO - A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic germ-cell tumors: The CABA-GCT study	Giulia Baciarello	ESMO
Présentation orale	652O - Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial	Christian Pfister	ESMO
Poster	Salvage SBRT for local prostate cancer recurrence after radiotherapy: a GETUG retrospective study.	G. Martinage	ESTRO
Présentation orale	Darolutamide maintenance in mCRPC previously treated with novel hormonal agents and non-progressive on taxane: randomized phase II trial (SAKK 08/16)	Richard Cathomas	SOHC